In recent years, several studies showed the effectiveness and safety of the AdVance sling for the treatment of male stress urinary incontinence (SUI). In 2010 the second generation of Advance, the AdVance XP was introduced. Aim of the study was to evaluate the efficacy and safety of the AdVance XP sling in male SUI after radical prostatectomy in a prospective multicenter study.
INTRODUCTION AND OBJECTIVES:
In recent years, several studies showed the effectiveness and safety of the AdVance sling for the treatment of male stress urinary incontinence (SUI). In 2010 the second generation of Advance, the AdVance XP was introduced. Aim of the study was to evaluate the efficacy and safety of the AdVance XP sling in male SUI after radical prostatectomy in a prospective multicenter study.
METHODS: In total 115 patients were included. Patients with urine nocturnal incontinence, previous incontinence surgery, previous radiotherapy and coaptive zone <1cm in the preoperative repositioning test were excluded. Postoperatively, a standardized 24-hour-pad test, quality of life scores (IQOL and ICIQ-UI SF), VAS for pain, IIEF5, IPSS and PGI-score were performed. All patients with 0-5g in the pad test were defined as cured and improved with a reduction of urine loss >50%. All others were classified as failures. Significance analysis was performed with the help of Wilcoxon-test.
RESULTS: Mean preoperative urine loss in the 24h pad-test was 272.0 g (median 272.0 g). After a follow-up of 3 months (n¼ 114) 64.9% of the patients were cured and 31.6% improved. Mean urine loss decreased significantly to 34.9 g (p<.001). After a followup of 24 months (n¼ 80) 68.8% of the patients were cured and 22.5% improved. Mean urine loss decreased significantly to 19.1 g (p<.001). After a follow-up of 36 months (n¼ 47) 66.0% of the patients were cured and 23.4% improved. Mean urine loss decreased significantly to 21.8 g (p<.001). After a follow-up of 48 months (n¼ 15) 60.0% of the patients were cured and 20% improved. Mean urine loss decreased significantly to 21.8 g (p<.001). There were no lost to follow-up. Overall patients reported of no relevant pain (mean VAS: 0.5) and the patients' satisfaction was high (mean PGI: 1.5). Mean I-QoL and ICIQ-UI SF improved significantly (p<.001, respectively) at maximum follow-up. There were no significant postoperative changes in IIEF5 and IPSS. No intraoperative and no long-term complications occurred. No erosion or explanations occurred.
CONCLUSIONS: The AdVance XP shows good and stable effectiveness and low complication rates even in a mid-term follow-up of up to 4 years. Our results though highlight the importance of adequate preoperative patient selection. Activator. The control pack consists of a printed circuit board, stepper motor and a nickel-cadmium cell in a titanium casing. The valve assembly consists of a cable link, plunger and urethral cuff. The control pack opens and closes the plunger via a drive assembly which adjusts the closure pressure magnitude, allowing post-implant adjustments (via telemetry) without the need for re-operation. The handheld activator communicates with the implanted control pack via Bluetooth technology. The activator allows for either the physician or patient to communicate with the FCD for daily operation or diagnostics. Daily operations of the device are recorded and remote tele-monitoring is available.
METHODS: The newest FCD prototype was implanted into 11 female mongrel dogs. The study length began at 12 weeks of observation after implantation for the initial animal and is extended to a 1 year follow-up for the most recent implants. There was no attempt to make the animals incontinent. Evaluations include renal ultrasound for each animal as well as weekly CBC, BMP and UA. Software and device performance was evaluated by telemetrically acquired data. Histology of explanted devices at the end of protocol is performed for each implant.
RESULTS: The successful surgical implantation of 32 previous devices has allowed the development of the newest Bluetooth controlled AUS. We have currently implanted 11 animals with the newest prototype. Successful telemetry has been established for all implants. No device infections or urethral erosions were seen. There was one cutaneous erosion of the control pack. 3 animals developed urinary retention. Two cases were related to tissue overgrowth in the valve cap resulting in urethral kinking and the remaining case was due to a software malfunction causing elevated closure pressure on the urethra with associated loss of communication with the device. This observation was identified through post hoc analysis of the telemetry data. The implanted devices have undergone over 3,560 activation cycles to date. The device has also generated over 1,100 status reports, allowing the investigator to monitor device function.
CONCLUSIONS: The successful development of a fluid-free remotely controlled AUS that allows for post-implant adjustable settings and remote tele-monitoring capabilities is possible. Further modifications to the prototype to reduce battery size and the risk of urinary retention are needed prior to human trials. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e627
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